Oncology and Hematology

Episodes 97-112 of 296

• 

  RestartResume

  Cracking the CRS Code in Myeloma: Insights from a Comprehensive Case Review

  RestartResume

  Cracking the CRS Code in Myeloma: Insights from a Comprehensive Case Review

  CME/CE

  Cracking the CRS Code in Myeloma: Insights from a Comprehensive Case Review

  0.25 credits

  • 

    

    Caitlin Costello, MD

  • 

    

    Sagar Lonial, MD, FACP

  0.25 credits

• 

  RestartResume

  Treating mCRPC with Lutetium-177 and Radium-223: Expert Insights

  RestartResume

  Treating mCRPC with Lutetium-177 and Radium-223: Expert Insights

  Project Oncology®

  Treating mCRPC with Lutetium-177 and Radium-223: Expert Insights

  • 

    

    Alan Bryce, MD

• 

  RestartResume

  Cannabis Extract and Melanoma: Insights into Cell Death Mechanisms

  RestartResume

  Cannabis Extract and Melanoma: Insights into Cell Death Mechanisms

  DermConsult

  Cannabis Extract and Melanoma: Insights into Cell Death Mechanisms

• 

  RestartResume

  A Roadmap to Safe and Effective Bispecific Antibody Use in Myeloma: Mitigating and Managing Adverse Events

  RestartResume

  A Roadmap to Safe and Effective Bispecific Antibody Use in Myeloma: Mitigating and Managing Adverse Events

  CME/CE

  A Roadmap to Safe and Effective Bispecific Antibody Use in Myeloma: Mitigating and Managing Adverse Events

  0.25 credits

  • 

    

    Caitlin Costello, MD

  • 

    

    Sagar Lonial, MD, FACP

  0.25 credits

• 

  RestartResume

  Bispecific Antibodies: The Newest Immunotherapy on the Block for RRMM

  RestartResume

  Bispecific Antibodies: The Newest Immunotherapy on the Block for RRMM

  MinuteCE®

  Bispecific Antibodies: The Newest Immunotherapy on the Block for RRMM

  1.00 program credit

  • 

    

    Sagar Lonial, MD, FACP

  • 

    

    Caitlin Costello, MD

  1.00 program credit

• 

  RestartResume

  Integrating Bispecific Antibodies Into Clinical Practice

  RestartResume

  Integrating Bispecific Antibodies Into Clinical Practice

  MinuteCE®

  Integrating Bispecific Antibodies Into Clinical Practice

  1.00 program credit

  • 

    

    Sagar Lonial, MD, FACP

  • 

    

    Caitlin Costello, MD

  1.00 program credit

• 

  RestartResume

  Efficacy Data for Bispecific Antibodies in RRMM

  RestartResume

  Efficacy Data for Bispecific Antibodies in RRMM

  MinuteCE®

  Efficacy Data for Bispecific Antibodies in RRMM

  1.00 program credit

  • 

    

    Sagar Lonial, MD, FACP

  1.00 program credit

• 

  MinuteCE®

  Bispecific Antibodies: A New Frontier in the Care of Patients With Refractory Multiple Myeloma 

  1.00 credit 10 episodes

  • 

    

    Sagar Lonial, MD, FACP

  • 

    

    Caitlin Costello, MD

  1.00 credit 10 episodes

• 

  RestartResume

  Case: Treatment Selection for ROS1-Rearranged NSCLC Patient with Brain Metastases

  RestartResume

  Case: Treatment Selection for ROS1-Rearranged NSCLC Patient with Brain Metastases

  MinuteCE®

  Case: Treatment Selection for ROS1-Rearranged NSCLC Patient with Brain Metastases

  1.00 program credit

  • 

    

    Charu Aggarwal, MD, MPH

  • 

    

    Alexander Drilon, MD

  1.00 program credit

• 

  RestartResume

  Intracranial Activity of ROS1 TKIs

  RestartResume

  Intracranial Activity of ROS1 TKIs

  MinuteCE®

  Intracranial Activity of ROS1 TKIs

  1.00 program credit

  • 

    

    Charu Aggarwal, MD, MPH

  1.00 program credit

• 

  RestartResume

  Step-Up Dosing of Bispecific Antibodies: The Need for Hospitalization

  RestartResume

  Step-Up Dosing of Bispecific Antibodies: The Need for Hospitalization

  MinuteCE®

  Step-Up Dosing of Bispecific Antibodies: The Need for Hospitalization

  1.00 program credit

  • 

    

    Sagar Lonial, MD, FACP

  • 

    

    Caitlin Costello, MD

  1.00 program credit

• 

  RestartResume

  Later-Line Targeted Therapies for ROS1 Fusion-Positive Lung Cancers

  RestartResume

  Later-Line Targeted Therapies for ROS1 Fusion-Positive Lung Cancers

  MinuteCE®

  Later-Line Targeted Therapies for ROS1 Fusion-Positive Lung Cancers

  1.00 program credit

  • 

    

    Alexander Drilon, MD

  1.00 program credit

• 

  RestartResume

  Overcoming Acquired TKI-Resistance with Next-generation ROS1-TKI Agents

  RestartResume

  Overcoming Acquired TKI-Resistance with Next-generation ROS1-TKI Agents

  MinuteCE®

  Overcoming Acquired TKI-Resistance with Next-generation ROS1-TKI Agents

  1.00 program credit

  • 

    

    Charu Aggarwal, MD, MPH

  • 

    

    Alexander Drilon, MD

  1.00 program credit

• 

  RestartResume

  Safety and Tolerability of ROS1 Tyrosine Kinase Inhibitors

  RestartResume

  Safety and Tolerability of ROS1 Tyrosine Kinase Inhibitors

  MinuteCE®

  Safety and Tolerability of ROS1 Tyrosine Kinase Inhibitors

  1.00 program credit

  • 

    

    Charu Aggarwal, MD, MPH

  1.00 program credit

• 

  MinuteCE®

  Next-Generation TKI Therapy for ROS1-Rearranged NSCLC

  1.00 credit 9 episodes

  • 

    

    Charu Aggarwal, MD, MPH

  • 

    

    Alexander Drilon, MD

  1.00 credit 9 episodes

• 

  RestartResume

  Approved Bispecific Antibodies for RRMM: Review of the Pivotal Trials   

  RestartResume

  Approved Bispecific Antibodies for RRMM: Review of the Pivotal Trials   

  MinuteCE®

  Approved Bispecific Antibodies for RRMM: Review of the Pivotal Trials   

  1.00 program credit

  • 

    

    Sagar Lonial, MD, FACP

  • 

    

    Caitlin Costello, MD

  1.00 program credit

• Previous
• 1
• 2
• …
• 5
• 6
• 7
• 8
• 9
• …
• 18
• 19
• Next